Aortic valve atresia

disease
On this page

Also known as aortic valve atresia (disease)congenital aortic valve atresiacongenital atresia of aortic valve

Summary

Aortic valve atresia (MONDO:0019808) is a disease with 1 cohort gene.

At a glance

  • Cohort genes: 1
  • ClinVar variants: 1

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

FieldValue
Canonical nameaortic valve atresia
Mondo IDMONDO:0019808
Orphanet95448
ICD-111700740306
NCITC98818
SNOMED CT51442005
UMLSC0265843
MedGen451016
GARD0019260
MedDRA10066801
Is cancer (heuristic)no

Also known as: aortic valve atresia · aortic valve atresia (disease) · congenital aortic valve atresia · congenital atresia of aortic valve

Data availability: 1 ClinVar variant · 1 HPO phenotype.

Disease family

Classification path: disease › human disease › disease by body system or component › cardiovascular disorderheart disordercongenital heart diseaseaortic valve atresia

Related subtypes (22): congenital heart defects, multiple types, heart septal defect, tetralogy of fallot, heart defects-limb shortening syndrome, tricuspid atresia, patent ductus arteriosus, coronary artery congenital malformation, mitral atresia disorder, persistent truncus arteriosus, dextro-looped transposition of the great arteries, congenital pulmonary veins anomaly, mehta lewis patton syndrome, structural congenital heart disease, multiple types - GATA4, GATA6-related congenital heart disease with or without pancreatic agenesis or neonatal diabetes, GATA5-related congenital heart defects, RBFOX2-related congenital heart disorder, syndromic congenital heart disease, ACTC1-related distal arthrogryposis with congenital heart disease, HAND1 related congenital heart defect, HAND2 related congenital heart defect, TFAP2B-related congenital heart disease spectrum disorder, PLD1-related congenital heart disease

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

ClinVar germline variants

1 retrieved; paginated sample, class counts are floors:

1 benign/likely benign

ClinVarVariant (HGVS)GeneClassificationReview
55847NM_001349338.3(FOXP1):c.1702C>T (p.Pro568Ser)FOXP1Benign/Likely benigncriteria provided, multiple submitters, no conflicts

Genes & proteins

Mendelian disease overlap and somatic drivers

GenCC: 0 · Orphanet: 3 · OMIM-shared: 0 · Dual-evidence (GWAS+Mendelian): 0

Orphanet rare-disease linkage (cohort genes)

GeneOrphanet IDRare disease
FOXP1Orphanet:391372FOXP1 Syndrome
FOXP1Orphanet:52417MALT lymphoma
FOXP1Orphanet:585877B-lymphoblastic leukemia/lymphoma with recurrent genetic abnormality

Cohort genes → proteins

1 cohort genes, 1 distinct canonical proteins.

Evidence partition

SubsetGenes
multi_evidence1

Cohort genes (full)

SymbolHGNCEnsemblUniProtNameEvidence
FOXP1HGNC:3823ENSG00000114861Q9H334Forkhead box protein P1clinvar

Cohort function summary

Lead sentence per gene, UniProt-curated.

SymbolProtein nameFunction (lead sentence)
FOXP1Forkhead box protein P1Transcriptional repressor.

Protein-family classification

Druggable: 0 · Difficult: 1 · Unknown: 0 · Druggable fraction: 0.0

Family distribution

Cohort families vs a genome-wide background (hypergeometric, BH-FDR; fold = observed/expected). Counts kept; sorted by enrichment, so the catch-all Other/Unknown bucket no longer leads.

FamilyGenesFoldFDR
Transcription factor18.3×0.121

Per-gene assignment

SymbolFamilyDruggable?ECInterPro (top 3)
FOXP1Transcription factornoFork_head_dom, TF_fork_head_CS_2, FOXP-CC

Expression context

Cohort genes with no expression data: 0.

1 cohort gene are a single-cell marker in ≥1 SCXA experiment.

Breadth distribution (Bgee present_calls)

BucketGenes
narrow (1-5 tissues)0
moderate (6-20)0
broad (>20)1
unknown0

Top tissues across cohort

TissueCohort genes
cardia of stomach1
oviduct epithelium1
pancreatic ductal cell1

Per-gene tissue summary (top 30)

SymbolBgee breadthFANTOM5 breadthSCXATop tissues
FOXP1256ubiquitousmarkerpancreatic ductal cell, oviduct epithelium, cardia of stomach

Protein interactions among cohort

Intra-cohort edges: 0.

Hub genes (top 10 by interactor count)

SymbolInteractor count
FOXP12,939

Structural data

PDB: 1 · AlphaFold-only: 0 · No structure: 0

Cohort genes with PDB structures (top 30)

SymbolUniProtPDB entries
FOXP1Q9H3341

Function

Pathway analysis

Distinct Reactome pathways touched by cohort: 1. Enrichment computed across 1 evidence-associated genes (1 with Reactome annotation).

Pathways by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 1 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

PathwayCohort genesFoldFDRSample cohort genes
Transcriptional regulation of pluripotent stem cells1543.8×0.002FOXP1

GO biological processes by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 1 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

GO termCohort genesFoldFDRSample cohort genes
regulation of macrophage colony-stimulating factor production116852.0×0.001FOXP1
regulation of monocyte differentiation18426.0×0.001FOXP1
regulation of defense response to bacterium18426.0×0.001FOXP1
positive regulation of interleukin-21 production15617.3×0.001FOXP1
regulation of chemokine (C-X-C motif) ligand 2 production15617.3×0.001FOXP1
regulation of interleukin-12 production14213.0×0.001FOXP1
positive regulation of hydrogen peroxide-mediated programmed cell death14213.0×0.001FOXP1
regulation of endothelial tube morphogenesis13370.4×0.001FOXP1
positive regulation of B cell receptor signaling pathway12407.4×0.001FOXP1
regulation of interleukin-1 beta production12106.5×0.001FOXP1
osteoclast development12106.5×0.001FOXP1
monocyte activation11872.4×0.001FOXP1
regulation of tumor necrosis factor production11685.2×0.001FOXP1
endothelial cell activation11685.2×0.001FOXP1
negative regulation of B cell apoptotic process11532.0×0.001FOXP1
negative regulation of cell growth involved in cardiac muscle cell development11404.3×0.001FOXP1
T follicular helper cell differentiation11404.3×0.001FOXP1
striatum development11123.5×0.002FOXP1
negative regulation of androgen receptor signaling pathway1936.2×0.002FOXP1
macrophage activation1702.2×0.002FOXP1
response to testosterone1468.1×0.003FOXP1
osteoclast differentiation1343.9×0.004FOXP1
positive regulation of smooth muscle cell proliferation1330.4×0.004FOXP1
positive regulation of endothelial cell migration1251.5×0.005FOXP1
regulation of inflammatory response1168.5×0.008FOXP1
cellular response to tumor necrosis factor1163.6×0.008FOXP1
response to lipopolysaccharide1124.8×0.009FOXP1
regulation of gene expression183.4×0.014FOXP1
negative regulation of gene expression169.1×0.016FOXP1
DNA damage response153.5×0.020FOXP1

Therapeutics

Drug target analysis

Approved (phase 4): 0 · Phase ≥3: 0 · Phased (≥1): 0 · Undrugged: 1

Druggability breadth: 0 of 1 evidence-associated genes (0%) have a ChEMBL target (buckets above are over the deeply-mined display cohort).

Top cohort targets by molecule count

SymbolMoleculesMax phase
FOXP100

Bioactivity and enzyme data

Enzyme cohort genes (≥1 EC): 0.

Pharmacogenomics

Cohort genes with a PharmGKB record: 1; with CPIC/DPWG dosing guidelines: 0.

No cohort gene has a CPIC/DPWG genotype-guided dosing guideline (PharmGKB).

Chemical tractability of cohort targets

0 approved/phased compounds have measured bioactivity against a cohort gene (and aren’t yet in disease-level trials). This is a research / tractability signal, NOT a therapeutic recommendation — a bioactivity row often reflects off-target or screening binding (e.g. promiscuous kinase inhibitors against a cohort kinase), implying no disease mechanism.

Druggability pyramid

Cohort genes binned by druggability tier (high → low):

TierDefinitionGenesSymbols
AApproved (phase 4 drug)0
BPhased (≥1) drug, not yet approved0
CDruggable family + PDB, no drug0
DDruggable family + AlphaFold only, no drug0
EDifficult family or no structure, no drug1FOXP1

Undrugged target profiles

1 cohort genes are undrugged. Ranked by ‘starting-point quality’ (assay depth + drugged-partner adjacency).

SymbolChEMBL assaysDrugged partners (top 3)
FOXP10

Clinical trials & evidence

Clinical trials

Clinical trials: 0.